Randomized double blind placebo control study of adjuvant treatment with the metalloproteinase inhibitor, Marimastat in patients with inoperable colorectal hepatic metastases: Significant survival advantage in patients with musculoskeletal side-effects

Anticancer Research

Volumn 23, Issue 1 B, 2003, Pages 639-645

  King, Julie ^a   Zhao, Jing ^a   Clingan, Phillip ^a   Morris, David ^a  

^a ST GEORGE HOSPITAL   (Australia)

Author keywords

Colorectal carcinoma; Marimastat; Matrix metaloproteinase; RCT; Unresectable liver metastases

Indexed keywords

DEXAMETHASONE; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; HEPARIN; MARIMASTAT; METALLOPROTEINASE INHIBITOR; PLACEBO; ANTINEOPLASTIC ANTIMETABOLITE; ENZYME INHIBITOR; HYDROXAMIC ACID; MATRIX METALLOPROTEINASE;

ADULT; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INOPERABLE CANCER; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; ADJUVANT CHEMOTHERAPY; AGED; CHEMICALLY INDUCED DISORDER; COLORECTAL TUMOR; DRUG ANTAGONISM; ENZYMOLOGY; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER TUMOR; METASTASIS; MIDDLE AGED; PATHOLOGY;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FEMALE; FLOXURIDINE; FLUOROURACIL; HUMANS; HYDROXAMIC ACIDS; INFUSIONS, INTRA-ARTERIAL; INFUSIONS, INTRAVENOUS; LIVER NEOPLASMS; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; MUSCULOSKELETAL DISEASES; PLACEBOS;

EID: 0037207968     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Parsons SL, Watson SA, Brown PD, Collins HM and Steele RJC: Matrix metalloproteinases. Brit J Surgery 84(2): 160-6, 1997.
2. Harris ED Jr: Rheumatoid arthritis: Patholophysiology and implications for therapy. New England J Med 322(18): 1277-89, 1990.
3. Mignatti P and Rifkin RB: Biology and biochemistry of proteinases in tumor invasion. Physiological Rev 73(1): 161-85, 1993.
4. Mori M, Barnard GF, Mimori K, Ueo H, Akiyoshi T and Sugimachi K: Overexpression of matrix metalloproteinase - 7 mRNA in human colon carcinomas. Cancer 75(6 suppl): 1516-9, 1995.
5. Troy A, Skelly M, Mulcahy HE et al: Matrix metalloproteinase mRNA levels in colorectal carcinoma: Correlation with clinico pathological features. Gut 41(Suppl 3): p. 929, 1997.
6. Murray GL, Duncan ME, O'Neil P, Melvin WT and Fothergill JE: Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nature Med 2(4): 461-2, 1996.
7. Zeng ZS and Guillem G: Distinct pattern of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase mRNA expression in human colorectal cancer and liver metastases. Brit J Cancer 72(3): 575-82, 1995.
8. Brown PD: Matrix metalloproteinases in gastrointestinal cancer. Gut 43(2): 161-3, 1998.
9. Watson S, Morris TM, Robinson G, Crimmin MJ, Brown PD and Hardcastle JD: Inhibition of organ invasion by the metalloproteinase inhibitor Batimastat (BB94) in two human colon carcinoma metastasis models. Cancer Res 55(16): 3629-3633, 1995.
10. Watson SA, Morris TM, Collins HM, Bawden LJ, Hawkins K and Bone EA: Inhibition of tumor growth by marimastat in a human xenograft model of gastric cancer: relationship with levels of circulating CEA. Brit J Cancer 81(1): 19-23, 1999.
11. millar AW, Brown PD, Moore J et al: Results of single and repeat dose studied of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers. Brit J Clinical Pharmacol 45(1): 21-6, 1998.
12. Nemunaitis J, Poole C, Primrose J et al: Combined analysis of the matrix metalloprotein inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer term study. Clin Cancer Res 5(4): 11011-9, 1998.
13. Heath EI and Grochow LB: Clinical potential of matrix metalloproteinase inhibitors in cancer therapy. Drugs 5(59): 1043-55, 2000.
14. Kaplan EL and Meier P: Nonparametric estimation from incomplete observations. J ASM Stat Ass 53: 457-81, 1958.
15. Hutchinson JW, Tierney GM, Parsons SL and Davis TR: Duputrens disease and frozen shoulder induced by treatment with matrix metalloproteinase inhibitor. J Bone Joint Surg Br 80: 907-80, 1998.
16. Fielding J, Scholefield R, Stuart R et al: A Randomized double blind controlled study of Marimastat in patients with inoperable gastric adenocarcinoma. Proc ASCO 19: 240a, 2000.
17. Primrose JN, Bleiberg H, Daniel F et al: Marimastat in recurrent colorectal cancer: exploratory evaluation of biological activity by measurement of CEA. Brit J Cancer 3-4(79): 509-14, 1999.
18. North H, King J and Morris DL: Effect of marimastat on serum tumor markers in patients with colorectal cancer. J Surgical Investigation 2(3): 213-7, 2000.
19. Oberg A, Hoyhtya M, Tavelin B and Stenling R: Limited value of preoperative serum analysis of matrix metalloproteinases (MMP-2 MMP9) and tissue inhibition of matrix metalloproteinases (TIMP 1, TIMP 2) in colorectal cancer. Anti Cancer Res 20: 1085-1092, 2000.
20. Yukana N, Yoshikawa T, Akaike M et al: Plasma concentration of tissue inhibitor of matrix metallproteinase 1 in patients with colorectal carcinoma. Brit J Surgery 88: 1592-1601, 2001.